Authors
Creative Biogene
Summary
CRISPR / Cas9 Platform, a global leading genetic editing biotechnology company, is committed to providing the most professional and comprehensive genetic editing technology solutions for our clients working on the editing of CRISPR/Cas9 genes. To support your projects, we offer a comprehensive custom CRISPR/Cas9 gene editing service from strategy design to final stable cell line.
Introduction
In the past decade, induced pluripotent stem cells (iPS) have revolutionized human disease models. The establishment of iPSCs as a useful method for studying different diseases suggests a clearer reflection of certain aspects of the human genetic defect disease phenotype rather than rodent models. At the same time, iPS-derived and differentiated cells enable researchers to study the effects of different cell types on health and disease, as well as biomarkers and therapeutic drug screening in the human genetic context.
Recently, the combination of induced pluripotent stem cells (iPSCs) and CRISPR technology has made a breakthrough in disease analysis and modeling. The simplicity and versatility of CRISPR are ideal for simulating many different diseases because it allows complex manipulation of genes in impossible ways. The functional knock-out model of PKD shows features such as cyst formation and podocyte tissue loss and cell junction integrity in iPSC-derived organoids. This has also led to an in vitro system that is easy to study nephrotoxicity, which is the most important obstacle in the design and testing of new drugs. In 2016, the CRISPR-Cas9 system was first used to mimic AD mutations, more faithfully mimicking the pathology of AD patients, and enhancing our understanding of the pathogenesis of these important diseases.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 284
- Comments 0